Nephros Inc

Nephros Inc (NEPH) Stock Analysis

$4.100

-0.173 (-4.21%)At close

Loading chart…
High
4.230
Open
4.110
VWAP
4.15
Vol
21.38K
Mkt Cap
22.04M
Low
4.105
Amount
88.61K
EV/EBITDA, TTM
8.61

Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.

AI analysis of Nephros Inc (NEPH)

buy

Nephros Inc is a good buy right now due to its recent strong performance, including a 15% sequential revenue increase to $6 million in Q2 2026 and a net income surge of over 400% to approximately $1.2 million. The stock is currently priced at $4.55, which is below the analyst target of $4, indicating potential upside. Additionally, the RSI is at 59.84, suggesting that the stock is nearing overbought territory but still has room for growth. The main risk is the company's current P/E ratio of 26.96, which indicates that the stock may be overvalued if growth does not accelerate as expected.

Valuation Metrics

The current forward P/E ratio for Nephros Inc (NEPH) is 0.00, compared to its 5-year average forward P/E of -23.52.

Forward P/E

Fair
5Y Average P/E
-23.52
Current P/E
0.00
Overvalued
115.81
Undervalued
-162.85

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
1.90
Current EV/EBITDA
8.61
Overvalued
28.56
Undervalued
-24.77

Forward P/S

Fair
5Y Average P/S
2.03
Current P/S
1.93
Overvalued
3.50
Undervalued
0.57

Alphio AI Price Scenarios for NEPH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NEPH

$3.45

Scenario price

B

Base

Base · 50%NEPH

$2.82

Scenario price

B

Bear

Bear · 25%NEPH

$2.02

Scenario price

Events Timeline

2026-08-06 (ET)

18:00:00

Nephros Reports Q2 Revenue of $6.02M

2026-02-13 (ET)

08:20:00

Nephros Enters Puerto Rican Market to Address Water Quality Needs

2025-12-11 (ET)

09:10:00

Nephros Launches Water Institute to Enhance Industry Education

2025-10-08 (ET)

09:11:53

Nephros Introduces New Filter for PFAS Removal

2024-10-24 (ET)

09:09:57

Nephros launches HydraGuard 20" UltraFilter

News

NEPH FAQ — answered by Alphio AI

Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. It operates in the Industrials sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nephros Inc is a good buy right now due to its recent strong performance, including a 15% sequential revenue increase to $6 million in Q2 2026 and a net income surge of over 400% to approximately $1.2 million. The stock is currently priced at $4.55, which is below the analyst target of $4, indicating potential upside. Additionally, the RSI is at 59.84, suggesting that the stock is nearing overbought territory but still has room for growth. The main risk is the company's current P/E ratio of 26.96, which indicates that the stock may be overvalued if growth does not accelerate as expected.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started